Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders

Markus Wolff, Katrine M. Johannesen, Ulrike B.S. Hedrich, Silvia Masnada, Guido Rubboli, Elena Gardella, Gaetan Lesca, Dorothée Ville, Mathieu Milh, Laurent Villard, Alexandra Afenjar, Sandra Chantot-Bastaraud, Cyril Mignot, Caroline Lardennois, Caroline Nava, Niklas Schwarz, Marion Gérard, Laurence Perrin, Diane Doummar, Stéphane AuvinMaria J. Miranda, Maja Hempel, Eva Brilstra, Nine Knoers, Nienke Verbeek, Marjan Van Kempen, Kees P. Braun, Grazia Mancini, Saskia Biskup, Konstanze Hörtnagel, Miriam Döcker, Thomas Bast, Tobias Loddenkemper, Lily Wong-Kisiel, Friedrich M. Baumeister, Walid Fazeli, Pasquale Striano, Robertino Dilena, Elena Fontana, Federico Zara, Gerhard Kurlemann, Joerg Klepper, Jess G. Thoene, Daniel H. Arndt, Nicolas Deconinck, Thomas Schmitt-Mechelke, Oliver Maier, Hiltrud Muhle, Beverly Wical, Claudio Finetti, Reinhard Brückner, Joachim Pietz, Günther Golla, Dinesh Jillella, Karen M. Linnet, Perrine Charles, Ute Moog, Eve Õiglane-Shlik, John F. Mantovani, Kristen Park, Marie Deprez, Damien Lederer, Sandrine Mary, Emmanuel Scalais, Laila Selim, Rudy Van Coster, Lieven Lagae, Marina Nikanorova, Helle Hjalgrim, G. Christoph Korenke, Marina Trivisano, Nicola Specchio, Berten Ceulemans, Thomas Dorn, Katherine L. Helbig, Katia Hardies, Hannah Stamberger, Peter De Jonghe, Sarah Weckhuysen, Johannes R. Lemke, Ingeborg Krägeloh-Mann, Ingo Helbig, Gerhard Kluger, Holger Lerche, Rikke S. Møller

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patchclamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.

Original languageEnglish (US)
Pages (from-to)1316-1336
Number of pages21
JournalBrain
Volume140
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Genetic Heterogeneity
Sodium Channel Blockers
Epilepsy
Mutation
Seizures
Phenotype
Therapeutics
Infantile Spasms
NAV1.2 Voltage-Gated Sodium Channel
Anticonvulsants
Myoclonic Epilepsy
Generalized Epilepsy
Partial Epilepsy
Status Epilepticus
Sodium Channels
Brain Diseases
Missense Mutation
Autistic Disorder
Age of Onset
Intellectual Disability

Keywords

  • epilepsy
  • epilepsy genetics
  • SCN2A
  • sodium channel blockers
  • treatment response

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Wolff, M., Johannesen, K. M., Hedrich, U. B. S., Masnada, S., Rubboli, G., Gardella, E., ... Møller, R. S. (2017). Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain, 140(5), 1316-1336. https://doi.org/10.1093/brain/awx054

Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. / Wolff, Markus; Johannesen, Katrine M.; Hedrich, Ulrike B.S.; Masnada, Silvia; Rubboli, Guido; Gardella, Elena; Lesca, Gaetan; Ville, Dorothée; Milh, Mathieu; Villard, Laurent; Afenjar, Alexandra; Chantot-Bastaraud, Sandra; Mignot, Cyril; Lardennois, Caroline; Nava, Caroline; Schwarz, Niklas; Gérard, Marion; Perrin, Laurence; Doummar, Diane; Auvin, Stéphane; Miranda, Maria J.; Hempel, Maja; Brilstra, Eva; Knoers, Nine; Verbeek, Nienke; Van Kempen, Marjan; Braun, Kees P.; Mancini, Grazia; Biskup, Saskia; Hörtnagel, Konstanze; Döcker, Miriam; Bast, Thomas; Loddenkemper, Tobias; Wong-Kisiel, Lily; Baumeister, Friedrich M.; Fazeli, Walid; Striano, Pasquale; Dilena, Robertino; Fontana, Elena; Zara, Federico; Kurlemann, Gerhard; Klepper, Joerg; Thoene, Jess G.; Arndt, Daniel H.; Deconinck, Nicolas; Schmitt-Mechelke, Thomas; Maier, Oliver; Muhle, Hiltrud; Wical, Beverly; Finetti, Claudio; Brückner, Reinhard; Pietz, Joachim; Golla, Günther; Jillella, Dinesh; Linnet, Karen M.; Charles, Perrine; Moog, Ute; Õiglane-Shlik, Eve; Mantovani, John F.; Park, Kristen; Deprez, Marie; Lederer, Damien; Mary, Sandrine; Scalais, Emmanuel; Selim, Laila; Van Coster, Rudy; Lagae, Lieven; Nikanorova, Marina; Hjalgrim, Helle; Korenke, G. Christoph; Trivisano, Marina; Specchio, Nicola; Ceulemans, Berten; Dorn, Thomas; Helbig, Katherine L.; Hardies, Katia; Stamberger, Hannah; De Jonghe, Peter; Weckhuysen, Sarah; Lemke, Johannes R.; Krägeloh-Mann, Ingeborg; Helbig, Ingo; Kluger, Gerhard; Lerche, Holger; Møller, Rikke S.

In: Brain, Vol. 140, No. 5, 01.05.2017, p. 1316-1336.

Research output: Contribution to journalArticle

Wolff, M, Johannesen, KM, Hedrich, UBS, Masnada, S, Rubboli, G, Gardella, E, Lesca, G, Ville, D, Milh, M, Villard, L, Afenjar, A, Chantot-Bastaraud, S, Mignot, C, Lardennois, C, Nava, C, Schwarz, N, Gérard, M, Perrin, L, Doummar, D, Auvin, S, Miranda, MJ, Hempel, M, Brilstra, E, Knoers, N, Verbeek, N, Van Kempen, M, Braun, KP, Mancini, G, Biskup, S, Hörtnagel, K, Döcker, M, Bast, T, Loddenkemper, T, Wong-Kisiel, L, Baumeister, FM, Fazeli, W, Striano, P, Dilena, R, Fontana, E, Zara, F, Kurlemann, G, Klepper, J, Thoene, JG, Arndt, DH, Deconinck, N, Schmitt-Mechelke, T, Maier, O, Muhle, H, Wical, B, Finetti, C, Brückner, R, Pietz, J, Golla, G, Jillella, D, Linnet, KM, Charles, P, Moog, U, Õiglane-Shlik, E, Mantovani, JF, Park, K, Deprez, M, Lederer, D, Mary, S, Scalais, E, Selim, L, Van Coster, R, Lagae, L, Nikanorova, M, Hjalgrim, H, Korenke, GC, Trivisano, M, Specchio, N, Ceulemans, B, Dorn, T, Helbig, KL, Hardies, K, Stamberger, H, De Jonghe, P, Weckhuysen, S, Lemke, JR, Krägeloh-Mann, I, Helbig, I, Kluger, G, Lerche, H & Møller, RS 2017, 'Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders', Brain, vol. 140, no. 5, pp. 1316-1336. https://doi.org/10.1093/brain/awx054
Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 2017 May 1;140(5):1316-1336. https://doi.org/10.1093/brain/awx054
Wolff, Markus ; Johannesen, Katrine M. ; Hedrich, Ulrike B.S. ; Masnada, Silvia ; Rubboli, Guido ; Gardella, Elena ; Lesca, Gaetan ; Ville, Dorothée ; Milh, Mathieu ; Villard, Laurent ; Afenjar, Alexandra ; Chantot-Bastaraud, Sandra ; Mignot, Cyril ; Lardennois, Caroline ; Nava, Caroline ; Schwarz, Niklas ; Gérard, Marion ; Perrin, Laurence ; Doummar, Diane ; Auvin, Stéphane ; Miranda, Maria J. ; Hempel, Maja ; Brilstra, Eva ; Knoers, Nine ; Verbeek, Nienke ; Van Kempen, Marjan ; Braun, Kees P. ; Mancini, Grazia ; Biskup, Saskia ; Hörtnagel, Konstanze ; Döcker, Miriam ; Bast, Thomas ; Loddenkemper, Tobias ; Wong-Kisiel, Lily ; Baumeister, Friedrich M. ; Fazeli, Walid ; Striano, Pasquale ; Dilena, Robertino ; Fontana, Elena ; Zara, Federico ; Kurlemann, Gerhard ; Klepper, Joerg ; Thoene, Jess G. ; Arndt, Daniel H. ; Deconinck, Nicolas ; Schmitt-Mechelke, Thomas ; Maier, Oliver ; Muhle, Hiltrud ; Wical, Beverly ; Finetti, Claudio ; Brückner, Reinhard ; Pietz, Joachim ; Golla, Günther ; Jillella, Dinesh ; Linnet, Karen M. ; Charles, Perrine ; Moog, Ute ; Õiglane-Shlik, Eve ; Mantovani, John F. ; Park, Kristen ; Deprez, Marie ; Lederer, Damien ; Mary, Sandrine ; Scalais, Emmanuel ; Selim, Laila ; Van Coster, Rudy ; Lagae, Lieven ; Nikanorova, Marina ; Hjalgrim, Helle ; Korenke, G. Christoph ; Trivisano, Marina ; Specchio, Nicola ; Ceulemans, Berten ; Dorn, Thomas ; Helbig, Katherine L. ; Hardies, Katia ; Stamberger, Hannah ; De Jonghe, Peter ; Weckhuysen, Sarah ; Lemke, Johannes R. ; Krägeloh-Mann, Ingeborg ; Helbig, Ingo ; Kluger, Gerhard ; Lerche, Holger ; Møller, Rikke S. / Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. In: Brain. 2017 ; Vol. 140, No. 5. pp. 1316-1336.
@article{d246f35d22764f80be1a7a30cbe9ee0d,
title = "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders",
abstract = "Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patchclamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.",
keywords = "epilepsy, epilepsy genetics, SCN2A, sodium channel blockers, treatment response",
author = "Markus Wolff and Johannesen, {Katrine M.} and Hedrich, {Ulrike B.S.} and Silvia Masnada and Guido Rubboli and Elena Gardella and Gaetan Lesca and Doroth{\'e}e Ville and Mathieu Milh and Laurent Villard and Alexandra Afenjar and Sandra Chantot-Bastaraud and Cyril Mignot and Caroline Lardennois and Caroline Nava and Niklas Schwarz and Marion G{\'e}rard and Laurence Perrin and Diane Doummar and St{\'e}phane Auvin and Miranda, {Maria J.} and Maja Hempel and Eva Brilstra and Nine Knoers and Nienke Verbeek and {Van Kempen}, Marjan and Braun, {Kees P.} and Grazia Mancini and Saskia Biskup and Konstanze H{\"o}rtnagel and Miriam D{\"o}cker and Thomas Bast and Tobias Loddenkemper and Lily Wong-Kisiel and Baumeister, {Friedrich M.} and Walid Fazeli and Pasquale Striano and Robertino Dilena and Elena Fontana and Federico Zara and Gerhard Kurlemann and Joerg Klepper and Thoene, {Jess G.} and Arndt, {Daniel H.} and Nicolas Deconinck and Thomas Schmitt-Mechelke and Oliver Maier and Hiltrud Muhle and Beverly Wical and Claudio Finetti and Reinhard Br{\"u}ckner and Joachim Pietz and G{\"u}nther Golla and Dinesh Jillella and Linnet, {Karen M.} and Perrine Charles and Ute Moog and Eve {\~O}iglane-Shlik and Mantovani, {John F.} and Kristen Park and Marie Deprez and Damien Lederer and Sandrine Mary and Emmanuel Scalais and Laila Selim and {Van Coster}, Rudy and Lieven Lagae and Marina Nikanorova and Helle Hjalgrim and Korenke, {G. Christoph} and Marina Trivisano and Nicola Specchio and Berten Ceulemans and Thomas Dorn and Helbig, {Katherine L.} and Katia Hardies and Hannah Stamberger and {De Jonghe}, Peter and Sarah Weckhuysen and Lemke, {Johannes R.} and Ingeborg Kr{\"a}geloh-Mann and Ingo Helbig and Gerhard Kluger and Holger Lerche and M{\o}ller, {Rikke S.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1093/brain/awx054",
language = "English (US)",
volume = "140",
pages = "1316--1336",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders

AU - Wolff, Markus

AU - Johannesen, Katrine M.

AU - Hedrich, Ulrike B.S.

AU - Masnada, Silvia

AU - Rubboli, Guido

AU - Gardella, Elena

AU - Lesca, Gaetan

AU - Ville, Dorothée

AU - Milh, Mathieu

AU - Villard, Laurent

AU - Afenjar, Alexandra

AU - Chantot-Bastaraud, Sandra

AU - Mignot, Cyril

AU - Lardennois, Caroline

AU - Nava, Caroline

AU - Schwarz, Niklas

AU - Gérard, Marion

AU - Perrin, Laurence

AU - Doummar, Diane

AU - Auvin, Stéphane

AU - Miranda, Maria J.

AU - Hempel, Maja

AU - Brilstra, Eva

AU - Knoers, Nine

AU - Verbeek, Nienke

AU - Van Kempen, Marjan

AU - Braun, Kees P.

AU - Mancini, Grazia

AU - Biskup, Saskia

AU - Hörtnagel, Konstanze

AU - Döcker, Miriam

AU - Bast, Thomas

AU - Loddenkemper, Tobias

AU - Wong-Kisiel, Lily

AU - Baumeister, Friedrich M.

AU - Fazeli, Walid

AU - Striano, Pasquale

AU - Dilena, Robertino

AU - Fontana, Elena

AU - Zara, Federico

AU - Kurlemann, Gerhard

AU - Klepper, Joerg

AU - Thoene, Jess G.

AU - Arndt, Daniel H.

AU - Deconinck, Nicolas

AU - Schmitt-Mechelke, Thomas

AU - Maier, Oliver

AU - Muhle, Hiltrud

AU - Wical, Beverly

AU - Finetti, Claudio

AU - Brückner, Reinhard

AU - Pietz, Joachim

AU - Golla, Günther

AU - Jillella, Dinesh

AU - Linnet, Karen M.

AU - Charles, Perrine

AU - Moog, Ute

AU - Õiglane-Shlik, Eve

AU - Mantovani, John F.

AU - Park, Kristen

AU - Deprez, Marie

AU - Lederer, Damien

AU - Mary, Sandrine

AU - Scalais, Emmanuel

AU - Selim, Laila

AU - Van Coster, Rudy

AU - Lagae, Lieven

AU - Nikanorova, Marina

AU - Hjalgrim, Helle

AU - Korenke, G. Christoph

AU - Trivisano, Marina

AU - Specchio, Nicola

AU - Ceulemans, Berten

AU - Dorn, Thomas

AU - Helbig, Katherine L.

AU - Hardies, Katia

AU - Stamberger, Hannah

AU - De Jonghe, Peter

AU - Weckhuysen, Sarah

AU - Lemke, Johannes R.

AU - Krägeloh-Mann, Ingeborg

AU - Helbig, Ingo

AU - Kluger, Gerhard

AU - Lerche, Holger

AU - Møller, Rikke S.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patchclamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.

AB - Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders. Here, we report the phenotypes of 71 patients and review 130 previously reported patients. We found that (i) encephalopathies with infantile/childhood onset epilepsies (≥3 months of age) occur almost as often as those with an early infantile onset (<3 months), and are thus more frequent than previously reported; (ii) distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients), Lennox-Gastaut not emerging from West syndrome (two patients), and focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients); and (iii) West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children). Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy. To assess the response to antiepileptic therapy, we retrospectively reviewed the treatment regimen and the course of the epilepsy in 66 patients for which well-documented medical information was available. We find that the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months), whereas other antiepileptic drugs were less effective. In contrast, sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening. Regarding the genetic findings, truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers. Functional characterization of four selected missense mutations using whole cell patchclamping in tsA201 cells-together with data from the literature-suggest that mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function, characterized by slowing of fast inactivation, acceleration of its recovery or increased persistent sodium current. Further, a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function. In contrast, mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects, including a depolarizing shift of voltage-dependent activation or a hyperpolarizing shift of channel availability (steady-state inactivation). Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy.

KW - epilepsy

KW - epilepsy genetics

KW - SCN2A

KW - sodium channel blockers

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=85019584830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019584830&partnerID=8YFLogxK

U2 - 10.1093/brain/awx054

DO - 10.1093/brain/awx054

M3 - Article

C2 - 28379373

AN - SCOPUS:85019584830

VL - 140

SP - 1316

EP - 1336

JO - Brain

JF - Brain

SN - 0006-8950

IS - 5

ER -